keyword
MENU ▼
Read by QxMD icon Read
search

Taxan

keyword
https://www.readbyqxmd.com/read/29678476/cabazitaxel-plus-lapatinib-as-therapy-for-her2-metastatic-breast-cancer-with-intracranial-metastases-results-of-a-dose-finding-study
#1
Denise A Yardley, Lowell L Hart, Patrick J Ward, Gail L Wright, Mythili Shastry, Lindsey Finney, Laura M DeBusk, John D Hainsworth
BACKGROUND: Lapatinib is an oral small molecule tyrosine kinase epidermal growth factor receptor-1/HER2 inhibitor that crosses the blood-brain barrier and is active against central nervous system (CNS) metastases. Cabazitaxel is a taxoid that is effective against taxane-resistant metastatic breast cancer (MBC) and has distinguished itself by its ability to cross the blood-brain barrier. The present phase II study (ClinicalTrials.gov identifier, NCT01934894) evaluated the combination of these agents to treat HER2+ MBC patients with CNS metastases...
March 8, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29678165/retrospective-analysis-of-the-impact-of-anthracycline-dose-reduction-and-chemotherapy-delays-on-the-outcomes-of-early-breast-cancer-molecular-subtypes
#2
Sigita Liutkauskiene, Saulius Grizas, Kristina Jureniene, Jorune Suipyte, Akvile Statnickaite, Elona Juozaityte
BACKGROUND: The objective of study was to determine the effect of anthracycline dose reduction and chemotherapy delays on 5-year overall survival in patients with stage I-III breast cancer, to establish the impact of molecular subtypes on the anthracycline modification effects and to analyze reasons for such chemotherapy scheme modifications. METHODS: Medical records of patients with stage I-III breast cancer were reviewed. Inclusion criteria involved stage I- III breast carcinoma; radical surgery performed and 4 courses of AC regimen (doxorubicin and cyclophosphamide), or at least 6 courses of FAC regimen (fluorouracil, doxorubicin and cyclophosphamide) completed; no neoadjuvant chemotherapy applied; no taxane group medications administered; medical records maintain comprehensive data on treatment and follow-up...
April 20, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29677569/validation-of-the-ajcc-8th-prognostic-system-for-breast-cancer-in-an-asian-healthcare-setting
#3
R X Wong, F Y Wong, John Lim, W X Lian, Y S Yap
AIMS: We aim to validate the AJCC 8th edition prognostic staging system for breast cancer in an Asian setting. METHODS: Clinico-pathologic information and cancer-specific survival (CSS) outcomes of 6287 stage I to III patients with invasive breast cancer who underwent upfront surgery at SingHealth institutions in Singapore from 2006 to 2014 were analyzed. Survival distributions for the different staging systems were estimated by the Kaplan-Meier method and compared using the log-rank tests...
April 17, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29675746/cabazitaxel-is-more-active-than-first-generation-taxanes-in-abcb1-cell-lines-due-to-its-reduced-affinity-for-p-glycoprotein
#4
George E Duran, Volker Derdau, Dietmar Weitz, Nicolas Philippe, Jörg Blankenstein, Jens Atzrodt, Dorothée Sémiond, Diego A Gianolio, Sandrine Macé, Branimir I Sikic
PURPOSE: The primary aim of this study was to determine cabazitaxel's affinity for the ABCB1/P-glycoprotein (P-gp) transporter compared to first-generation taxanes. METHODS: We determined the kinetics of drug accumulation and retention using [14 C]-labeled taxanes in multidrug-resistant (MDR) cells. In addition, membrane-enriched fractions isolated from doxorubicin-selected MES-SA/Dx5 cells were used to determine sodium orthovanadate-sensitive ATPase stimulation after exposure to taxanes...
April 19, 2018: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29670855/current-therapies-for-human-epidermal-growth-factor-receptor-2-positive-metastatic-breast-cancer-patients
#5
REVIEW
Alexey A Larionov
The median survival of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) has more than doubled, since the discovery of HER2-targeted treatments: it rose from less than 2 years in 2001 (prior introduction of trastuzumab) to more than 4 years in 2017. The initial generation of HER2-targeted therapies included trastuzumab with taxanes in the first line, followed by the addition of lapatinib and by a switch to another cytotoxic agent after progression. Results of CLEOPATRA, EMILIA, and TH3RESA trials have changed this clinical practice...
2018: Frontiers in Oncology
https://www.readbyqxmd.com/read/29664354/combined-taxane-based-chemotherapy-and-intensity-modulated-radiotherapy-with-simultaneous-integrated-boost-for-gastroesophageal-junction-adenocarcinoma
#6
Corrado Spatola, Alessandra Tocco, Antonio Pagana, Roberto Milazzotto, Raffaele Luigi, Vincenzo Salamone, Carmelo Militello, Marcello Migliore, Pietro Valerio Foti, Antonio Di Cataldo, Grazia Acquaviva, Giuseppe Privitera
We describe our experience, gained over the past 3 years, in the treatment of gastroesophageal junction adenocarcinoma, whose incidence has been increasing in recent years. In our series, we present the results to a follow-up of about 2 years for a total of 18 patients, treated with a particularly intensive combination treatment. It consists of neoadjuvant induction chemotherapy with the protocol docetaxel-cisplatin-5-fluorouracil for four cycles, before a concomitant chemoradiotherapy treatment. During combined phase, patients received an intensity-modulated radiotherapy and a weekly cisplatin...
March 2018: Future Oncology
https://www.readbyqxmd.com/read/29663729/hepatitis-b-infection-reported-with-cancer-chemotherapy-analyzing-the-us-fda-adverse-event-reporting-system
#7
Akimasa Sanagawa, Yuji Hotta, Tomoya Kataoka, Yasuhiro Maeda, Masahiro Kondo, Yoshihiro Kawade, Yoshihiro Ogawa, Ryohei Nishikawa, Masahiro Tohkin, Kazunori Kimura
We conducted data mining using the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database on spontaneously reported adverse events to evaluate the association between anticancer drug therapy and hepatitis B infection. Reports of hepatitis B infection were retrieved from the FAERS database. The reporting odds ratio (ROR) was used to estimate the association between hepatitis B infection and various anticancer agents and drug combinations. We detected statistically significant risk signals of hepatitis B for 33 of 64 anticancer agents by ROR (26 cytotoxicity drugs and seven molecular-targeted drugs)...
April 16, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29663331/three-cases-of-advanced-cutaneous-angiosarcoma-treated-with-eribulin-investigation-of-serum-soluble-cd163-and-cxcl10-as-possible-biomarkers-predicting-the-biological-behaviour-of-angiosarcoma
#8
T Fujimura, Y Sato, Y Kambayashi, K Tanita, A Tsukada, H Terui, A Hashimoto, S Aiba
Cutaneous angiosarcoma (CAS) is a highly aggressive vascular tumour that recurs locally and metastasizes early. Although chemoradiotherapy with taxanes shows a high response rate with prolonged survival, second-line therapy for advanced CAS remains contentious. This report describes three cases of advanced CAS treated with eribulin. In addition, we investigated serum sCD163, CXCL10 and CCL22 levels at several time points of tumour progression in these patients, revealing serum levels of sCD163 and CXCL10 as potential biomarkers for progression of CAS...
April 17, 2018: British Journal of Dermatology
https://www.readbyqxmd.com/read/29662002/carotenoid-lutein-selectively-inhibits-breast-cancer-cell-growth-and-potentiates-the-effect-of-chemotherapeutic-agents-through-ros-mediated-mechanisms
#9
Xiaoming Gong, Joshua R Smith, Haley M Swanson, Lewis P Rubin
Increasing evidence suggests that dietary carotenoids may reduce the risk of breast cancer. However, anti-breast cancer effects of carotenoids have been controversial, albeit understudied. Here, we investigated the effects of specific carotenoids on a wide range of breast cancer cell lines, and found that among several carotenoids (including β-carotene, lutein, and astaxanthin), lutein significantly inhibits breast cancer cell growth by inducing cell-cycle arrest and caspase-independent cell death, but it has little effect on the growth of primary mammary epithelial cells (PmECs)...
April 14, 2018: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/29661243/effect-of-neoadjuvant-chemotherapy-regimen-on-relapse-free-survival-among-patients-with-breast-cancer-achieving-a-pathologic-complete-response-an-early-step-in-the-de-escalation-of-neoadjuvant-chemotherapy
#10
Anna Weiss, Sami I Bashour, Kenneth Hess, Alastair M Thompson, Nuhad K Ibrahim
BACKGROUND: Patients with breast cancer who have a pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) have improved survival. We hypothesize that once pCR has been achieved, there is no difference in subsequent postsurgical recurrence-free survival (RFS), whichever NACT regimen is used. METHODS: Data from patients with breast cancer who achieved pCR after NACT between 1996 and 2011 were reviewed. RFS was estimated by the Kaplan-Meier method, and differences between groups were assessed using log-rank testing...
April 16, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29660543/scalp-cooling-successfully-prevents-alopecia-in-breast-cancer-patients-undergoing-anthracycline-taxane-based-chemotherapy
#11
Ines Vasconcelos, Alexandra Wiesske, Winfried Schoenegg
INTRODUCTION: Chemotherapy for breast cancer induces alopecia, representing a major source of patient distress. This study assesses whether a scalp-cooling device is effective in reducing chemotherapy-induced alopecia, and assesses adverse treatment effects. MATERIALS AND METHODS: A prospective observational study including women with breast cancer undergoing chemotherapy and scalp cooling using a Paxman device. The primary efficacy end points were: successful hair preservation (no hair loss; <30% hair loss not requiring a wig; or <50% hair loss not requiring a wig) at the completion of chemotherapy...
April 13, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29659077/total-choline-quantification-measured-by-1h-mr-spectroscopy-as-early-predictor-of-response-after-neoadjuvant-treatment-for-locally-advanced-breast-cancer-the-impact-of-immunohistochemical-status
#12
Stylianos Drisis, Patrick Flamen, Michael Ignatiadis, Thierry Metens, Shih-Li Chao, Marie Chintinne, Marc Lemort
BACKGROUND: Validation of new biomarkers is essential for the early evaluation of neoadjuvant treatments. PURPOSE: To determine whether measurements of total choline (tCho) by 1H spectroscopy could predict morphological or pathological complete response (pCR) of neoadjuvant treatment and whether breast cancer subgroups are related to prediction accuracy. STUDY TYPE: Prospective, nonrandomized, monocentric, diagnostic study. POPULATION: Sixty patients were initially included with 39 women participating in the final cohort...
April 16, 2018: Journal of Magnetic Resonance Imaging: JMRI
https://www.readbyqxmd.com/read/29658055/salvage-chemotherapy-with-the-combination-of-oxaliplatin-leucovorin-and-5-fluorouracil-in-advanced-gastric-cancer-refractory-or-intolerant-to-fluoropyrimidines-platinum-taxanes-and-irinotecan
#13
Chihiro Kondoh, Shigenori Kadowaki, Azusa Komori, Yukiya Narita, Hiroya Taniguchi, Takashi Ura, Masashi Ando, Kei Muro
BACKGROUND: Although nivolumab showed survival benefit in patients with advanced gastric cancer (AGC) progressing after standard chemotherapy, there is a lack of data regarding oxaliplatin-based chemotherapy in this clinical setting. METHODS: We retrospectively evaluated the efficacy and safety of oxaliplatin with l-leucovorin and bolus/continuous infusion of 5-fluorouracil as salvage treatment in patients with AGC refractory or intolerant to fluoropyrimidines, cisplatin, taxanes, and irinotecan...
April 16, 2018: Gastric Cancer
https://www.readbyqxmd.com/read/29649743/recent-advances-in-trimethoxyphenyl-tmp-based-tubulin-inhibitors-targeting-the-colchicine-binding-site
#14
REVIEW
Ling Li, Sibo Jiang, Xiaoxun Li, Yao Liu, Jing Su, Jianjun Chen
Microtubules (composed of α- and β-tubulin heterodimers) play a pivotal role in mitosis and cell division, and are regarded as an excellent target for chemotherapeutic agents to treat cancer. There are four unique binding sites in tubulin to which taxanes, vinca alkaloids, laulimalide and colchicine bind respectively. While several tubulin inhibitors that bind to the taxane or vinca alkaloid binding sites have been approved by FDA, currently there are no FDA approved tubulin inhibitors targeting the colchicine binding site...
April 5, 2018: European Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/29644504/impact-of-smoking-history-on-the-outcomes-of-women-with-early-stage-breast-cancer-a-secondary-analysis-of-a-randomized-study
#15
Omar Abdel-Rahman, Winson Y Cheung
To assess the impact of smoking history on the outcomes of early-stage breast cancer patients treated with sequential anthracyclines-taxanes in a randomized study. This is a secondary analysis of patient-level data of 1242 breast cancer patients referred for adjuvant chemotherapy in the BCIRG005 clinical trial. Overall survival was assessed according to smoking history through Kaplan-Meier analysis. Univariate and multivariate Cox regression analyses of factors affecting overall and relapse-free survival were subsequently conducted...
April 11, 2018: Medical Oncology
https://www.readbyqxmd.com/read/29642419/treatment-of-multidrug-resistant-leukemia-cells-by-novel-artemisinin-egonol-and-thymoquinone-derived-hybrid-compounds
#16
Lisa Gruber, Sara Abdelfatah, Tony Fröhlich, Christoph Reiter, Volker Klein, Svetlana B Tsogoeva, Thomas Efferth
Two major obstacles for successful cancer treatment are the toxicity of cytostatics and the development of drug resistance in cancer cells during chemotherapy. Acquired or intrinsic drug resistance is responsible for almost 90% of treatment failure. For this reason, there is an urgent need for new anticancer drugs with improved efficacy against cancer cells, and with less toxicity on normal cells. There are impressive examples demonstrating the success of natural plant compounds to fight cancer, such as Vinca alkaloids, taxanes, and anthracyclines...
April 6, 2018: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/29628983/-fcrr3a-158-polymorphism-and-stromal-tumor-infiltrating-lymphocytes-and-survival-among-patients-with-metastatic-her2-positive-breast-cancer-receiving-trastuzumab-based-treatment
#17
Heejung Chae, Changhoon Yoo, Jung-A Yoon, Hee Jin Lee, Kyu-Pyo Kim, Jeong-Eun Kim, Jin-Hee Ahn, Kyung Hae Jung, Gyungyub Gong, Sung-Bae Kim
Purpose: The prognosis of human epidermal growth factor receptor 2 (HER2)-positive breast cancer has markedly improved since the introduction of trastuzumab. We aimed to evaluate the association between stromal tumor-infiltrating lymphocyte (sTIL) or FcrR polymorphisms and survival among patients with metastatic HER2-positive breast cancer who were treated with trastuzumab. Methods: A total of 56 women with recurrent or metastatic HER2-positive breast cancer who received the trastuzumab-taxane combination as first-line treatment were included in this retrospective analysis...
March 2018: Journal of Breast Cancer
https://www.readbyqxmd.com/read/29627870/arterial-thrombosis-in-patients-with-cancer
#18
REVIEW
Mirela Tuzovic, Joerg Herrmann, Cezar Iliescu, Kostas Marmagkiolis, Boback Ziaeian, Eric H Yang
PURPOSE OF REVIEW: Cancer is a common cause of morbidity and mortality in the USA. While the association between venous thrombosis and malignancy is well established, arterial thrombosis has more recently been recognized as a serious complication of cancer and certain chemotherapeutic agents. This review aims to summarize the most recent literature regarding the incidence and risk factors for cancer-related arterial thrombosis, understand the pathophysiologic mechanisms of thrombosis, and highlight the specific diagnostic and treatment considerations relevant to cancer patients...
April 7, 2018: Current Treatment Options in Cardiovascular Medicine
https://www.readbyqxmd.com/read/29627688/chemosensitizing-effects-of-metformin-on-cisplatin-and-paclitaxel-resistant-ovarian-cancer-cell-lines
#19
Isabella Dos Santos Guimarães, Taciane Ladislau-Magescky, Nayara Gusmão Tessarollo, Diandra Zipinotti Dos Santos, Etel Rodrigues Pereira Gimba, Cinthya Sternberg, Ian Victor Silva, Leticia Batista Azevedo Rangel
BACKGROUND: Epithelial ovarian cancer (EOC) remains the most lethal gynecologic malignancy. Primary cytoreductive surgery with adjuvant taxane-platinum chemotherapy is the standard treatment to fight ovarian cancer, however, their side effects are severe, and chemoresistance emerges at high rates. Therefore, EOC clinic urges for novel treatment strategies to reverse chemoresistance and to improve the survival rates. Metformin has been shown to act in synergy with certain anti-cancer agents, overcoming chemoresistance in various types of tumors...
November 21, 2017: Pharmacological Reports: PR
https://www.readbyqxmd.com/read/29625257/5-year-overall-survival-after-early-breast-cancer-diagnosed-during-pregnancy-a-retrospective-case-control-multicentre-french-study
#20
A Ploquin, B Pistilli, E Tresch, J S Frenel, F Lerebours, A Lesur, C Loustalot, T Bachelot, M Provansal, J M Ferrero, F Coussy, M Debled, P Kerbrat, A Vinceneux, D Allouache, F Morvan, F Dalenc, S Guiu, R Rouzier, L Vanlemmens
BACKGROUND: Breast cancer diagnosed during pregnancy (BCP) is rare, but the prevalence is expected to rise. Long-term follow-up data regarding this clinically challenging condition are scarce. The main objective of this multicentre case-control French study was to compare the survival between pregnant patients and matched controls. METHODS: Patients from 27 centres diagnosed between 2000 and 2009 with histologically proven invasive breast cancer occurring during pregnancy were retrospectively included...
April 3, 2018: European Journal of Cancer
keyword
keyword
64691
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"